The official approval of a drug rarely resonates outside the circle of medical professionals and patients who stand to benefit from the new treatment. However, US biotech company Biogen has garnered attention due to its new drug, which was approved on Monday.
Its treatment aducanumab, which will now be known as Aduhelm, is the first new approved treatment for Alzheimer's disease for almost twenty years.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
More disappointment for Orphazyme as FDA rejects Niemann Pick C application
The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.
Orphazyme CEO silent on potential firings in wake of FDA rejection
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.
Top Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"
Biotech heavyweight Bo Jesper Hansen is very disappointed over the FDA rejection of Orphazyme's only drug candidate.
Orphazyme cuts guidance following FDA setback
Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.
US OTC hearing aid channel back on Department of Health agenda
The US health department aims to have a hearing on publishing the regulatory framework for selling hearing aids over the course of the year.
Employee for regulatory department 
Clinical Supply Manager/Specialist - Lundbeck 
Associate Director, Biostatistics - Genmab 
Senior CMC Expert/Senior CMC Project Manager - Klifo 
Global Medical Affairs Lead - Y-mAbs Therapeutics 
Associate Formulation Scientist, Oral Formulation Research - Novo Nordisk 
Chemist responsible for validation and qualification for Laboratory Automation Development 
(Senior) Regulatory Science Specialist - IWA Consulting 
Regulatory affairs life cycle specialist 
Analytical Coordinator (Senior scientist) – Permanent position, Symphogen